停止治疗的新生血管性年龄相关性黄斑变性患者的自然病程及与视力预后相关的因素
这项回顾性观察研究纳入35例(35眼)因持续性或复发性积液而停止抗血管内皮生长因子治疗的新生血管性年龄相关性黄斑变性患者,比较停药时与24个月时的最佳矫正视力。结果显示视力从停药时平均logMAR 1.02(Snellen等效20/209)降至24个月时1.60(20/796)(P < 0.001),且视网膜内液的存在与更差的24个月视力及视力变化程度相关。
要点
- 停药时平均logMAR最佳矫正视力为1.02(Snellen等效20/209),24个月时为1.60(20/796)(P < 0.001)。
- 息肉状脉络膜血管病变与其他新生血管性年龄相关性黄斑变性亚型之间的24个月最佳矫正视力无差异(P = 0.803)。
- 视网膜内液(有 vs 无)可预测24个月最佳矫正视力(P = 0.004)及最佳矫正视力变化程度(P = 0.043)。
核心结论
- 停药患者视力明显恶化,与新生血管性年龄相关性黄斑变性亚型无关。
- 视网膜内液的存在与更差的视力预后相关,作者认为有视网膜内液的患者在决定停药前应被强烈警告其不良预后。
研究设计与样本
- 回顾性观察研究,纳入35例(35眼)因持续性或复发性积液而停止抗血管内皮生长因子治疗的新生血管性年龄相关性黄斑变性患者。
主要发现
- 停药前平均抗血管内皮生长因子注射次数为4.0 ± 1.6次。
- 停药时平均logMAR最佳矫正视力为1.02 ± 0.20(Snellen等效20/209),24个月时为1.60 ± 0.56(20/796),差异有统计学意义(P < 0.001)。
- 息肉状脉络膜血管病变与其他新生血管性年龄相关性黄斑变性亚型之间的24个月最佳矫正视力无差异(P = 0.803)。
- 视网膜内液(有 vs 无)可预测24个月最佳矫正视力(P = 0.004)及最佳矫正视力变化程度(P = 0.043)。
临床怎么用
- 作者认为,有视网膜内液的患者在决定停止治疗前应被强烈警告其不良预后。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the 24-month natural course of visual changes in patients discontinuing treatment despite persistent or recurrent fluid and factors predictive of visual prognosis. METHODS: This retrospective, observational study included 35 patients (35 eyes) who initially received anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration (AMD), but discontinued treatment despite persistent or recurrent fluid. The best-corrected visual acuity (BCVA) at treatment discontinuation was determined and compared with the 24-month BCVA, which was then compared between polypoidal choroidal vasculopathy and other neovascular age-related macular degeneration subtypes. Baseline characteristics predictive of visual outcome and the degree of visual change were also analyzed. RESULTS: The mean number of anti-vascular endothelial growth factor injections before treatment discontinuation was 4.0 ± 1.6. The mean logarithm of minimal angle of resolution of BCVA at treatment discontinuation and that at 24 months were 1.02 ± 0.20 (Snellen equivalents = 20/209) and 1.60 ± 0.56 (20/796), respectively (P < 0.001). The 24-month BCVA was not different between polypoidal choroidal vasculopathy and other neovascular age-related macular degeneration subtypes (P = 0.803). The type of fluid (intraretinal fluid vs. no intraretinal fluid) was predictive of 24-month BCVA (P = 0.004) and the degree of changes in BCVA (P = 0.043). CONCLUSION: Marked deterioration in visual acuity was noted in patients discontinuing treatment, regardless of neovascular age-related macular degeneration subtypes. The presence of intraretinal fluid was associated with worse visual prognosis, suggesting that patients with intraretinal fluid should be strongly warned about their poor prognosis before they decide to discontinue treatment.
引用
- Kim JH, Chang YS, Kim JW, et al. NATURAL COURSE OF PATIENTS DISCONTINUING TREATMENT FOR AGE-RELATED MACULAR DEGENERATION AND FACTORS ASSOCIATED WITH VISUAL PROGNOSIS. Retina. 2017. PMID: 28092343. doi:10.1097/IAE.0000000000001494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。